2024-01-03 08:13:35 ET
DENVER, Colo., Jan. 3, 2024 ( www.247marketnews.com )- ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary, BioLite, Inc., stated, this morning, that they received an aggregate of 46 million shares from AiBtl BioPharma Inc. (“AiBtl”), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl, a private company, placed a value of $460 ($10 per share) on such payment, based on an independent third party valuation report.
ABVC BioPharma is trading at $1.91, up $0.71 (+59.17%), on 9.8M shares traded.
Its 52-week range is $0.6739 to $18.70. It hit a premarket high of $2.65 and this morning’s move is its biggest since October while today’s news seems to be more significant that that, …
The post $460M First Milestone Payment of Global Licensing Fees has this BioPharma Listing Flying appeared first on 24/7 market News .
For further details see:
$460M First Milestone Payment of Global Licensing Fees has this BioPharma Listing Flying